David Alan Campbell, President and CEO at Janux Therapeutics, Inc. (JANX), sold 15,000 shares at $67.00 ($1.0M) on 2024-12-03, disclosed to the SEC on 2024-12-03.
Scheduled sale ($1.0M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| JANX | SELL | 2024-12-27 | $1.4M | — | Filing → |
| JANX | SELL | 2024-11-27 | $2.6M | — | Filing → |
| JANX | SELL | 2024-10-30 | $2.7M | — | Filing → |